Research reveals underperformance of many Phase III oncology trials

New research in the September 2021 issue of JNCCN-;Journal of the National Comprehensive Cancer Network finds that more than 80% of therapies tested in Phase III oncology trials did not achieve meaningful clinical benefit in prolonging survival.

Generated by Feedzy